RHYTHM PHARMACEUTICALS, INC. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
David P. Meeker (CEO) and Hunter C. Smith (CFO) certified the Form 10-Q for the quarter ended September 30, 2026, on November 3, 2026. Both officers attest that financial statements fairly present the company's financial condition and results of operations, and that disclosure controls and internal control over financial reporting are effective. No material weaknesses or significant deficiencies in internal controls are disclosed.
Why this rating
Routine SOX 302/906 certifications; no substantive business changes, financial data, or control issues disclosed. Standard quarterly filing requirement.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.